COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights.
Viromed Medical AG plans to acquire pharmedix GmbH through a capital increase, expanding their healthcare portfolio. The acquisition aims for a revenue growth of 35% in 2025 -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value
Viromed Medical AG cancels acquisition of ActivCell Group AG, exploring more valuable strategic options. Focus shifts to advancing innovative medical device ViroCAP -
-
-
